National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for classical Hodgkin Lymphoma. HTA ID: 21013

Pembrolizumab  is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

NCPE Assessment Process Complete
Rapid review commissioned 29/03/2021
Rapid review completed 14/05/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

 

The HSE has approved reimbursement following confidential price negotiations February 2022.